Liberty Health Sciences Inc. is a vertically integrated cannabis producer and retailer operating in Florida with over 300 employees, 26 dispensaries, 190,000 square feet of cultivation space, and has been profitable since August 2019. The document provides an overview of Liberty's operations, production capacity, product offerings, retail footprint in Florida, and financial information including quarterly revenue figures showing steady growth since Q3 2019.

1. LibertyHealthSciences.com/Investors July 2020

2. LibertyHealthSciences.com/Investors July 2020
Disclaimer
This documentation is a presentation (the “Presentation”) of general background information about Liberty Health Sciences Inc.’s (“Liberty Health Sciences”) activities current as of July 2020. It is
information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment
objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate.
This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in
connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of Liberty Health Sciences
are remind ed that any such purchase or subscription must not be mad e on the basis of the information contained in this Presentation but are referred to the entire bod y of publicly disclosed
information regarding Liberty Health Sciences.
The information contained in this Presentation is derived solely from management of Liberty Health Sciences and otherwise publicly available information concerning Liberty Health Sciences and does
not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in Liberty Health Sciences. The information has
not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to Liberty Health Science’s publicly disclosed information. No
representation or warranty, express or implied, is made or given by or on behalf of Liberty Health Sciences or any of its affiliates, directors, officers or employees as to the accuracy, completeness or
fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions.
Liberty Health Sciences does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been
authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon
as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation.
The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax
adviser for legal, financial or tax advice.
Certain statements in this Presentation may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of applicable securities
laws. Forward-looking information may relate to Liberty Health Sciences’ future outlook and anticipated events or results and may include statements regarding Liberty Health Sciences’ financial
results, future financial position, expected growth of cash flows, business strategy, budgets, projected costs, projected capital expenditures, taxes, plans, objectives, potential synergies, industry trends
and growth opportunities. Often but not always, forward-looking information can be identified by the use of words such as “anticipate”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”,
“should”, “could”, “may”, “might”, “target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking information contained in this
Presentation is based on certain assumptions regard ing expected growth, results of operations, performance, ind ustry trend s and growth opportunities. Although management believes its
assumptions are reasonable, based on the information available, any assumptions could prove to be inaccurate.
Although Liberty Health Sciences has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements,
there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date hereof
and Liberty Health Sciences and its directors, officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results
or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Accordingly, you should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking information is expressly qualified in its entirety by this
cautionary statement.
Forward-looking information and other information contained herein concerning management’s general expectations concerning the medical marijuana industry are based on estimates prepared by
management using data from publicly available industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which
management believes to be reasonable. However, this data is inherently imprecise, although generally indicative of relative market positions, market shares and performance characteristics. While
management is not aware of any misstatements regarding any industry data presented herein, industry data is subject to change based on various factors.
This Presentation may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or
distributed in any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of applicable securities
law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and Liberty Health Science does not accept liability to any person in relation thereto.

3. Summary
Liberty Health Sciences Inc. is a producer and retailer of cannabis products aimed at improving the quality of peoples’ lives.
GROWING SINCE 2017 TEAM MEMBERS 300+ COMING SOON
14 Upcoming
Dispensaries
MONTHLY TRANSACTIONS
50,000+
RETAIL IN FLORIDA
115,000 sq. ft.
CULTIVATION IN
FLORIDA
190,000 sq. ft.
DISPENSARIES
26 Dispensaries:
Ranked #4 in Florida
PROCESSING &
MANUFACTURING
50,000 sq. ft.
GMP CERTIFIED
2020-2021
PROFITABLE SINCE
August 2019
VERTICAL CANNABIS
LICENSE IN FLORIDA
LibertyHealthSciences.com/Investors July 2020

4. florida market
 Cancer
 Epilepsy
 Glaucoma
 HIV/AIDS
 Post-traumatic stress disorder (PTSD)
 Amyotrophic lateral sclerosis (ALS)
 Crohn´s disease
 Parkinsons´s disease
 Multiple sclerosis (MS)
 Medical conditions of the same kind or class as or
comparable to the others listed.
 A terminal condition diagnosed by a physician other
than the qualified physician issuing the physician
certification.
 Chronic nonmalignant pain caused by a quailing
medical condition or that originates from a qualifying
medical condition and persist beyond the usual course
of that qualifying medical condition.
POPULATION 21,480,000 MARKET
EST. US $1.6 BILLION
BY 2022
DISPENSARIES
STATEWIDE 254
QUALIFYING
PATIENTS 6 MILLION
(30%)
MEDICAL USE ONLYREGISTERED
ACTIVE PATIENTS
358,052+
PHYSICIANS
ORDERING
2,457+
NO OF
LICENSES 22
LibertyHealthSciences.com/Investors July 2020
Qualifying conditions

5. Liberty Operations
LibertyHealthSciences.com/Investors July 2020
Production Location: Gainesville, Florida
Total Acreage: 387
40 acres currently in use
247 acres available for expansion
100 acres wetland (unavailable)
Cultivation Production Capacity: 19,500 kg per year
Harvest per Week: 3,500 – 5,000 Plants
Flower Yield per Plant: 40g (Dry)
Manufacturing Capacity
Flower Packaging 1020 units per hour
Oil Filling & Capping 900 units per hour
YTD Patients Served: 84,000+
New Patients per Month: 4,900+
Average Monthly Patient Visit: 2.1
Average Ticket Size: $96
Average Basket size: 3-4 Items
Retail Inventory Turn: 88%+
Sales Delivery: 4%

6. Smokable Flower
Cartridges
Concentrates
Oral Solutions
Capsules
Topicals
Accessories &
Merchandise
Sales by Category:
54%
26%
8%
4%
4%
2%
2%
LibertyHealthSciences.com/Investors July 2020

7. Bonita Springs
Cape Coral
Dania Beach
Gainesville
Merritt Island
Miami
North Miami
Orange Park
Palm Harbor Port
St. Lucie
St. Petersburg
Summerfield
Tallahassee
Tampa (LoCicero)
Tampa (Tetra)
Winter Haven
Boca Raton
Panama City
Pensacola
Sarasota
Bradenton
Lakeland
Orlando
Stuart
West Palm Beach
Jacksonville Beach
Dispensaries (26)
HUBS (7)
Dania Beach
Bonita Springs
Merritt Island
Gainesville
Tallahassee
Miami
St. Petersburg
Retail
Footprint
LibertyHealthSciences.com/Investors July 2020

8. LibertyHealthSciences.com/Investors July 2020
*SUBJECT TO Florida DEPARTMENT OF HEALTH APPROVAL
Processing&
EXTRACTION
METHODS
CAPABILITIES finished
Products
ORAL SOLUTIONS
CONCENTRATES
FLOWER
CAPSULES
PODS
TOPICALS
CO2
terpene extraction
Ethanol Extraction*
fractionation
distillation
isolation
nano-emulsion
micro-encapsulation
Carbon filtration
VAPORIZER CARTRIDGES
DISPOSABLE VAPORIZERS
Full spectrum
distillate*
crystallization*
isolates*

9. ly
our

10. 0.5m
5m
4m
3m
2m
1m
6m
7m
$4.1M
$1.1M $1.3M
$1.7M $2.1M $2.3M
$3.5M $3.4M
$4.8M$4.5M $4.6M $4.6M
JUL19 AUG 19 SEP 19 OCT 19 NOV 19 DEC 19 JAN 20 FEB 20MAR 19
ACTUAL
APR 19 MAY 19 JUN 19
ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL
ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL ACTUAL
MAR 19 APR 19 MAY 19 JUN 19 JUL 19 AUG 19 SEP 19 OCT 19 NOV 19 DEC 19 JAN 20 FEB 20 FY 20
US MILLIONS
Month over
Month Increase
$1.1M $1.3M $1.7M $2.1M $2.3M $3.5M $3.4M $4.5M $4.6M $4.6M $4.8M $4.1M $38.1M
24% 30% 21% 11% 54% -3% 31% 3% 1% 4% -14%
SALES
FY 2020
LibertyHealthSciences.com/Investors July 2020
REVENUE

11. cultivation

12. harvest

13. Processing

14. Flower
Packaging

15. Manufacturing

16. liberty health sciences
 Email - IR@libertyhealthsciences.com
 Visit - libertyhealthsciences.com/Investors
 Call - 833.254.4877